Chiara Tarantelli
Overview
Explore the profile of Chiara Tarantelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
726
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tarantelli C, Kayali O, Civanelli E, Cascione L, Mensah A, Folloni C, et al.
Hematol Oncol
. 2025 Mar;
43(2):e70055.
PMID: 40040616
The PIM family of serine/threonine kinases (PIM1, PIM2, and PIM3) are involved in the development of cancer and represent promising therapeutic targets. We investigated the therapeutic potential of targeting PIM...
2.
Arribas A, Napoli S, Gaudio E, Herbaux C, Cannas E, Tarantelli C, et al.
Blood Adv
. 2024 Oct;
8(24):6268-6281.
PMID: 39374583
CD37-directed antibody and cellular-based approaches have shown preclinical and promising early clinical activity. Naratuximab emtansine (Debio 1562; IMGN529) is an antibody-drug conjugate (ADC) incorporating an anti-CD37 monoclonal antibody conjugated to...
3.
Spriano F, Tarantelli C, Cascione L, Gaudio E, Golino G, Scalise L, et al.
Br J Haematol
. 2024 Jul;
205(5):1873-1882.
PMID: 39080847
Camidanlumab tesirine (ADCT-301) is a CD25-specific antibody-drug conjugate (ADC) employing SG3199, a highly cytotoxic DNA minor groove cross-linking pyrrolobenzodiazepine dimer. The ADC has shown early clinical antitumour activity in various...
4.
Spriano F, Sartori G, Sgrignani J, Barnabei L, Arribas A, Guala M, et al.
Haematologica
. 2024 Jun;
109(11):3602-3614.
PMID: 38899342
Hematologic cancers are among the most common cancers in adults and children. Despite significant improvements in therapies, many patients still succumb to the disease. Therefore, novel therapies are needed. The...
5.
Licenziato L, Mazzone E, Tarantelli C, Accornero P, Rinaldi A, Divari S, et al.
Animals (Basel)
. 2024 May;
14(10).
PMID: 38791684
B-cell lymphomas (BCL) is the most frequent hematological cancer in dogs. Treatment typically consists of chemotherapy, with CHOP-based protocols. However, outcome remains generally poor, urging the exploration of new therapeutic...
6.
Tarantelli C, Wald D, Munz N, Spriano F, Bruscaggin A, Cannas E, et al.
Haematologica
. 2024 May;
109(10):3314-3326.
PMID: 38721745
Antibody-drug conjugates (ADC) represent one of the most successful therapeutic approaches introduced into clinical practice in the last few years. Loncastuximab tesirine (ADCT-402) is a CD19-targeting ADC in which the...
7.
Forestieri G, de Almeida J, Napoli S, Piffaretti D, Tarantelli C, Zhang F, et al.
Hematol Oncol
. 2024 Apr;
42(3):e3275.
PMID: 38650582
No abstract available.
8.
Zammarchi F, Havenith K, Sachini N, Janghra N, Chivers S, Idusogie E, et al.
Mol Cancer Ther
. 2024 Feb;
23(4):520-531.
PMID: 38324336
Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and lymphomas have poor patient outcomes; novel therapies are needed. CD22 is an attractive target for antibody-drug conjugates (ADCs), being highly...
9.
Arribas A, Napoli S, Cascione L, Barnabei L, Sartori G, Cannas E, et al.
Mol Cancer Ther
. 2023 Dec;
23(3):368-380.
PMID: 38052765
BTK and PI3K inhibitors are among the drugs approved for the treatment of patients with lymphoid neoplasms. Although active, their ability to lead to long-lasting complete remission is rather limited,...
10.
Arribas A, Gaudio E, Napoli S, Yvon Herbaux C, Tarantelli C, Bordone R, et al.
bioRxiv
. 2023 Nov;
PMID: 38014209
Purpose: The transmembrane protein CD37 is expressed almost exclusively in lymphoid tissues, with the highest abundance in mature B cells. CD37-directed antibody- and, more recently, cellular-based approaches have shown preclinical...